Anton-2009.jpg  


Anton Neschadim, Hon. B.Sc., M.Sc., Ph.D.

1121 Bay Street, Suite 1906, Toronto, ON, Canada, M5S 3L9, Phone: (416) 897-2789

Lab: 67 College Street, 4th Floor, Room 4-453, Toronto, ON, Canada, M5G 2M1

E-mail: anton.neschadim@utoronto.ca

 

Academic Preparation

 

  Ph.D. in Medical Biophysics, Faculty of Medicine, University of Toronto, 2005-2011

Area of Research: Gene Therapy, Immunology, Transplantation

  M.Sc. in Immunology, Faculty of Medicine, University of Toronto, 2002-2005

Area of Research: Immunology, B Lymphocyte Development

  Hon. B.Sc. in Life Sciences, Faculty of Arts and Science, University of Toronto, 1999-2002

Programs: Immunology Specialist & Biological Chemistry Specialist

  Rogozin High School Matriculation Diploma, Tel-Aviv, Israel, 1995-1998

 

 

Publications (Peer-Reviewed)

 

Citations – 197, h-index – 7

 

§  Neschadim, A., Pritzker, L.B., Pritzker, K.P.H., Branch, D., Summerlee, A.J.S., Trachtenberg, J., Silvertown, J.D. Relaxin receptor antagonist (AT-001) synergizes with docetaxel via downregulation of the hypoxia response in androgen-independent prostate cancer. Submitted to Cancer Cell, 2013. (Impact Factor = 24.755)

§  Purohit, M.K., Chakka, S.K., Scovell, I., Neschadim, A., Salum, N., Katsman, Y., Bareau, M.C., Branch, D.R., Kotra, L.P. Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias. Submitted to Journal of Medicinal Chemistry. 2013. (Impact Factor = 5.614)

§  Sato, T. *, Neschadim, A. *, Lavie, A., Yanagisawa, T., Medin, J.A. The Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis Offers Efficient Bystander Cell Killing for Suicide Gene Therapy of Cancer. PLoS One. 8(10): e78711. (*Equal contributor). (Impact Factor = 3.730)

§  Purohit, M., Scovell, I., Neschadim, A., Katsman, Y., Branch, D., Kotra, L. Disulfide Linked Pyrazole Derivatives Inhibit Phagocytosis of Opsonized blood cells. Bioorganic Medicinal Chemistry Letters. 2013. 23(8): 2324-7. (Impact Factor = 2.338)

§  Neschadim, A., Wang, J.C.M., Lavie, A., Medin, J.A. Bystander killing of malignant cells via the delivery of novel thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer Gene Therapy. 2012. 19(5): 320-327. (Impact Factor = 2.945)

§  Neschadim, A., Wang, J.C.M., Sato, T., Fowler, D.H., Lavie, A., Medin, J.A. Cell Fate Control Gene Therapy based on Engineered Variants of Human Deoxycytidine Kinase. Molecular Therapy. 2012. 20(5):1002-1013. (Impact Factor = 7.041)

§  Walia, J.S.*, Neschadim, A.*, Lopez, O., Alayoubi, A., Fan, X., Madden, M., Lee, C-J., Cheung, F, Jaffray, D., Levade, T., McCart, A.J., Medin, J.A. Supranormal Lysosomal Acid Ceramidase Activity in Primates after Autologous Transplant of Lentivector-Transduced Hematopoietic Cells. Human Gene Therapy. 2010. 22(6): 679-687. (*Equal contributor). (Impact Factor = 4.019)

§  Scaife, M.D., Pacienza, N.A., Devine, S.P., Scheid, L., Lee, C-J., Lopez-Perez, O., Neschadim, A., Foley, R., Medin, J.A. Engineered Human Tmpk Fused with Truncated Cell Surface Markers: Versatile Cell-Fate Control Safety Cassettes. Gene Therapy. 2012. (Impact Factor = 4.321)

§  Likar, Y., Zurita, J., Shenker, L., Cai, S., Neschadim, A., Medin, J.A., Hricak, H., Ponomarev, V. A new pyrimidine-specific human reporter gene – mutated deoxycytidine kinase suitable for PET imaging in patients treated with acycloguanosine-based cytotoxic drugs. Journal of Nuclear Medicine. 2010. 51(9):1395-1403. (Impact Factor = 5.774)

§  Silvertown, J.D., Neschadim, A., Liu, H.N., Shannon, P., Walia, J.S., Kao, J.C.H., Robertson, J., Summerlee, A.J.S., and J.A. Medin. Relaxin-3 and receptors in the human and rhesus brain and reproductive tissues. Regulatory Peptides. 2010.  159:44-53. (Impact Factor = 2.056)

§  Scaife, M.D., Neschadim, A., Fowler, D.H., Medin, J.A. Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opinion in Biological Therapy. 2009. 9(6):749-61. Review. (Impact Factor = 3.345)

§  Neschadim, A., McCart, J.A., Keating, A., Medin, J.A. A Roadmap to Safe, Efficient, and Stable Lentivirus-Mediated Gene Therapy with Hematopoietic Cell Transplantation. Biology of Bone and Marrow Transplantation. 2007. 13(12):1407-16. Review. (Impact Factor = 3.940)

§  Sato, T., Neschadim, A., Konrad, M., Lavie, A., and J.A. Medin. Engineered Human tmpk/AZT As a Novel Enzyme/Prodrug Axis for Suicide Gene Therapy. Molecular Therapy. 2007. 15(5): 962-70. (Impact Factor = 7.041)

§  Silvertown, J.D., Symes J.C., Neschadim, A., Nonaka, T., Kao, J., Summerlee, A.J.S., and J.A. Medin. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J. 2007. 21(3): 754-65. (Impact Factor = 5.704)

§  Neschadim, A., and M.J.H. Ratcliffe. Failure of Immunoglobulin Heavy and Light Chain Association and Consequences to Apoptosis in the Bursa of Fabricius. Manuscript in preparation, Dept. of Immunology, University of Toronto, Ontario, CA, 2005.

 

 

Abstracts and Presentations

 

§  Branch, D., Purohit, M., Scovell, I., Neschadim, A., Katsman, Y., Kotra, L. Small molecule inhibitors of phagocytosis for treatment of immune cytopenias. 2013. Experimental Hematology. 41(8): S66-S66.

§  Neschadim, A., Lavie, A., Sato, T., Fowler, D.H., Ponomarev, V., Medin, J.A. Next-Generation Lentiviral Cell Fate Control Gene Therapy based on Engineered Human deoxyCytidine Kinase. Presentation, James Lepock Memorial Student Symposium, Department of Medical Biophysics, 2010.

§  Neschadim, A., Lavie, A., Sato, T., Fowler, D.H., Ponomarev, V., Medin, J.A. Next-Generation Lentiviral Cell Fate Control Gene Therapy Based on Engineered Variants of Human Deoxycytidine Kinase. American Society of Gene Therapy 13th Annual Meeting 2010. Oral Presentation.

§  Sato, T., Neschadim, A., Sukegawa, J., Yanagisawa, T., Medin, J.A. Mechanisms of the Tmpk/AZT-System Bystander Effect; Cell Fate Control Gene Therapy for Anti-Cancer Treatment. American Society of Gene and Cell Therapy 13th Annual Meeting, 2010.

§  Sato, T., Neschadim, A., Medin, J. A., & Yanagisawa, T. Gap junction-mediated bystander killing highlights the utility of the TMPK/AZT system for cancer suicide gene therapy. 2010. Journal of Gene Medicine. 12(12): 1052-1053.

§  Scaife, M.D., Devine, S.P., Neschadim, A., Pacienza, N.A., Medin, J.A. Lentiviral Vector Correction of Fabry Disease Encompassing a Cell Fate Control Safety Element. American Society of Gene and Cell Therapy 13th Annual Meeting 2010.

§  Scaife, M.D., Devine, S.P., Neschadim, A., Pacienza, N.A., Fowler, D.H., Medin, J.A. Truncated CD19 Fused with Mutant Human Tmpk: A Versatile Cell Fate Control Safety Cassette. American Society of Gene and Cell Therapy 13th Annual Meeting, 2010.

§  Likar, Y., Zurita, J., Shenker, L., Moroz, M., Cai, S., Neschadim, A., Medin, J., Hricak, H., Sadelain, M., Ponomarev, V. A New Human-Derived Reporter Gene Suitable for Clinical PET Imaging of T-Cell Trafficking. American Society of Gene and Cell Therapy 13th Annual Meeting, 2010.

§  Neschadim, A., How to Enunciate the Importance of Research Funding to the General Populace and the Government. Geneva Park Retreat, Department of Medical Biophysics, University of Toronto, 2009.

§  Neschadim, A., Scaife, M.D, Devine, S.P., Lavie, A., Sato, T., Fowler, D.H., Medin, J.A. Lentiviral Cell Fate Control Gene Therapy based on Engineered Human Kinases. Southern Ontario Gene Therapy Meeting 2009.

§  Likar, Y., Zurita, J., Dobrenkov, K., Shenker, L., Neschadim, A., Medin, J.A., Cai, S., Hricak, H., Ponomarev, V. A new pyrimidine-specific human-derived reporter gene for PET imaging in humans: truncated mutant deoxycytidine kinase. Abstract submitted to World Molecular Imaging Congress 2009.

§  Medin, J.A., Walia, J.S., Neschadim, A., Fan, X., Madden, M., Cheung, F., Jaffray, D., Levade, T., Brady, R.O., McCart, A.J. Outcomes of testing Lentivector-mediated Gene Therapy for Farber Disease in Non-Human Primates. Abstract in Molecular Genetics and Metabolism. 2008.

§  Neschadim, A., Lavie, A., Sato, T., Fowler, D.H., Medin, J.A. Novel Lentiviral Cell Fate Control Gene Therapy Based on Engineered Variants of the Human Deoxycytidine Kinase. American Society of Gene Therapy 11th Annual Meeting 2008.

§  Devine, S.P., Neschadim, A., Fowler, D.H., Lavie, A., Medin, J.A. Towards a Master Cell Fate Control Lentiviral Vector for Cell and Gene Therapy. American Society of Gene Therapy 11th Annual Meeting 2008.

§  Walia, J.S., Neschadim, A., Ramsubir, S., Yoshimitsu, M., Head, R., Rasaiah, V.I., Donahue, R.E., Cheung, F., Jaffray, D., McCart J.A., Medin, J.A. Acid Ceramidase Expression at Supranormal Levels in Non-Human Primates Following Autologous Transplantation of Lentivirus-Transduced Hematopoietic Cells. American Society of Gene Therapy 11th Annual Meeting 2008.

§  Sato, T., Neschadim, A., Sukegawa, J., Yanagisawa, T., Medin, J.A. Bystander Killing Highlights the Utility of the tmpkF105Y/AZT System for Suicide Gene Therapy of Cancer. American Society of Gene Therapy 11th Annual Meeting 2008.

§  Neschadim, A., Sato, T., Fowler, D.H., Lavie, A., and J.A. Medin. Development of improved lentiviral suicide gene therapy for the management of GvHD in allogeneic BMT. American Society of Hematology 48th Annual Meeting, Florida. 2006. Blood. 2006. 108: 3256.

§  Sato, T., Neschadim, A., Rasaiah, V., Konrad, M., Lavie, A., Medin, J.A. Development of a novel lentivirus-based suicide gene therapy approach using modified human thymidylate monophosphate kinase. 2006. Journal of Gene Medicine. 8(3): 399.

§  Neschadim, A., Konrad, M., Lavie, A., and J.A. Medin. Novel ‘Suicide’ Gene Therapy Approaches for the Prevention of GvHD. Presented at the 2006 Langdon Hall Gene Therapy Meeting, Cambridge, Ontario, CA, 2006 – Awarded Best Poster.

§  Neschadim, A., Improved Lentiviral 'Suicide' Gene Therapy for the Management Of GvHD in Allogeneic Bone Marrow Transplantation. Student Seminars, Dept. of Medical Biophysics, University of Toronto, Ontario, CA, 2006.

§  Sato, T., Neschadim, A., Rasaiah, V., Konrad, M., Fowler, D.H., Lavie, A., and J. A. Medin. A novel suicide gene therapy approach for reduction of GvHD using lentiviral delivery of a modified human thymidylate monophosphate kinase. Blood. 2005. 106(11): 397B.

§  Sato, T., Neschadim, A., Rasaiah, V., Konrad, M., Fowler, D.H., Lavie, A., and J. A. Medin. Improved suicide gene therapy: Lentiviral gene transfer of equine herpes virus type 4 thymidine kinase into target cells. 2005. Blood. 106(11): 396B-397B.

§  Neschadim, A. Failure of Immunoglobulin Heavy and Light Chain Pairing May Underlie Bursal B Cell Death. Student Seminars, Dept. of Immunology, University of Toronto, Ontario, CA, 2004.

§  Neschadim, A. B Lymphocyte Selection During Development. Presented at Immunology Graduate Poster Session, Dept. of Immunology, University of Toronto, Ontario, CA, 2003.

§  Neschadim, A. Synthesis of Diaryl Ethers by Copper Catalyzed Coupling of Aryl Alcohols with Potassium Phenyltrifluoroborate Salts. Presented at AstraZeneca Undergraduate Poster Session, University of Toronto, Ontario, CA, 2001.

 

 

Theses

 

§  Neschadim, A. Development of Novel Cell Fate Control Gene Therapy for Applications in Cancer and Immune Disorders. Department of Medical Biophysics. University of Toronto. 2011.

§  Neschadim, A. Failure of Immunoglobulin Heavy and Light Chain Pairing and Consequences for Cell Death in the Bursa of Fabricius. Department of Immunology. University of Toronto. 2005.

 

 

Patents and Patent Applications

 

§  Neschadim, A., Silvertown, J.D. USA Provisional 61916528. Methods of treating cancer associated with relaxin. Provisional filed: 2013.

§  Medin, J.A., Neschadim, A. US20100233200 - Vector encoding therapeutic polypeptide and safety elements to clear transduced cells - PCT/CA2008/000579. PCT filed: 2008. (Change to inventors processed at USPTO.)

 

 

Awards, Honors, Grants and Scholarships

 

§  MITACS – Enterprise, 2013

§  Ontario Centres of Excellence – First Job Award, 2011

§  BioTalent Canada – Career Focus Award, 2011

§  Ontario Centres of Excellence – First Job Award, 2011

§  CIHR Scholarship, Training Program in Regenerative Medicine Award, 2010

§  University of Toronto School of Graduate Studies, Doctoral Thesis Completion Grant, 2010

§  American Society of Gene and Cell Therapy, 13th Annual Meeting, Travel Award, 2010

§  McCuaig-Throop Bursary, School of Graduate Studies, 2009

§  CIHR Scholarship, Training Program in Regenerative Medicine Award, 2005 - 2008

§  Presentation Award, Day in Transplantation and Immunology, MOT Program, TGH, 2008

§  University of Toronto Open Fellowships, UofT, 2002 - 2008

§  Best Poster Award, Langdon Hall Gene Therapy Meeting, 2006

§  Travel Award, XVI International AIDS Conference, 2006

§  Princess Margaret Hospital Foundation, OSOTF, 2006-2010

§  Travel Award, 1st Student Conference on Biomedical Computing, 2006

§  Reuben Wells Leonard Scholarship in Physics, UofT, 2002

§  Robert and Jean Hadgraft Scholarship in Chemistry, UofT, 2002

§  OSOTF (Richard Ivey Foundation) Summer Research Award, UofT, 2001

§  William Robert Luscombe Bursary, UofT, 2001

§  Dr. James A. & Connie P. Dickson Scholarship in the Sciences & Mathematics, UofT, 2000

§  University of Toronto Dean's List, 2000, 2001